Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Update: Supply Interruption of DOXIL® (doxorubicin HCl liposome injection)

Johnson & Johnson has announced that it is likely the Doxil shortage will continue through the end of 2014. They announced that their main supplier of Doxil has decided to close their plant and discontinue production of Doxil. Due to FDA approval process, Johnson & Johnson will be unable to have a new supplier it seems before the end of 2014. (http://www.ovariancancer.org/2013/10/17/doxil-shortage-update/ )

(10/14/13)

More info: http://www.doxilsupply.com/index.html

As a follow-up to my September 25th update, today we began to notify healthcare professionals of distributor-level supply outages of DOXIL in the U.S. This is due to an issue at our third-party manufacturer, Ben Venue Laboratories, Inc., which is disappointing given our commitment to patients and their physicians to ensure sufficient supplies of DOXIL.

Information

This entry was posted on November 19, 2013 by in In the News and tagged , .

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada

%d bloggers like this: